Infectious Complications of Targeted Therapies in Children with Leukemias and Lymphomas

• Published in: Cancers 2022-10, Vol.14 (20), p.5022
• Main Authors: Kyriakidis, Ioannis, Mantadakis, Elpis, Stiakaki, Eftichia, Groll, Andreas H, Tragiannidis, Athanasios
• Format: Article
• Language: English
• Subjects: Acute lymphoblastic leukemia; Bortezomib; Cancer in children; Cell therapy; Chemotherapy; Children; Complications and side effects; Cytomegalovirus; Cytotoxicity; Disease; Drug targeting; Drug therapy; FDA approval; Gemtuzumab ozogamicin; Hematopoietic stem cells; Hypogammaglobulinemia; Imatinib; Immune reconstitution; Immune system; Immunosuppression; Infections; Leukemia; Lymphatic leukemia; Lymphocytes T; Lymphoma; Lymphomas; Monoclonal antibodies; Non-Hodgkin's lymphoma; Patients; Pediatric research; Pediatrics; Pembrolizumab; Prophylaxis; Review; Rituximab; Sepsis; Stem cell transplantation
• ISSN: 2072-6694; 2072-6694
• DOI: 10.3390/cancers14205022

The aim of this review is to highlight mechanisms of immunosuppression for each agent, along with pooled analyses of infectious complications from the available medical literature. Rituximab confers no increase in grade ≥3 infectious risks, except in the case of patients with advanced-stage non-Hodgkin lymphoma. Gemtuzumab ozogamicin links with high rates of grade ≥3 infections which, however, are comparable with historical cohorts. Pembrolizumab exhibits a favorable safety profile in terms of severe infections. Despite high rates of hypogammaglobulinemia (HGG) with blinatumomab, low-grade ≥3 infection rates were observed, especially in the post-reinduction therapy of relapsed B-acute lymphoblastic leukemia. Imatinib and nilotinib are generally devoid of severe infectious complications, but dasatinib may slightly increase the risk of opportunistic infections. Data on crizotinib and pan-Trk inhibitors entrectinib and larotrectinib are limited. CAR T-cell therapy with tisagenlecleucel is associated with grade ≥3 infections in children and is linked with HGG and the emergence of immune-related adverse events. Off-label therapies inotuzumab ozogamicin, brentuximab vedotin, and venetoclax demonstrate low rates of treatment-related grade ≥3 infections, while the addition of bortezomib to standard chemotherapy in T-cell malignancies seems to decrease the infection risk during induction. Prophylaxis, immune reconstitution, and vaccinations for each targeted agent are discussed, along with comparisons to adult studies.